Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Annals of Surgical Oncology

Volumn 22, Issue 4, 2015, Pages 1118-1127

  Ataseven, Beyhan ^a   Lederer, Bianca ^b   Blohmer, Jens U ^c   Denkert, Carsten ^d   Gerber, Bernd ^e   Heil, Jörg ^f   Kühn, Thorsten ^g   Kümmel, Sherko ^h   Rezai, Mahdi ^a   Loibl, Sibylle ^b   von Minckwitz, Gunter ^b  

^a KLINIKEN ESSEN MITTE   (Germany)

^b Headquarters   (Germany)

^c St Gertrauden Hospital   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^f Interdisciplinary Breast Center   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h Breast Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TUMOR BIOPSY; TUMOR CLASSIFICATION; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; MASTECTOMY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN;

EID: 84925538092     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4122-7     Document Type: Article

References (29)

1. Anastassiades O, Iakovou E, Stavridou N, Gogas J, Karameris A. Multicentricity in breast cancer. A study of 366 cases. Am J Clin Pathol. 1993;99:238–43.
2. Egan RL. Multicentric breast carcinomas: clinical-radiographic-pathologic whole-organ studies and 10-year survival. Cancer. 1982;49:1123–30.
3. Fisher ER, Gregorio R, Redmond C, Vellios F, Sommers SC, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4): I. Observations concerning the multicentricity of mammary cancer. Cancer. 1975;35:247–54.
4. McDivitt RW. Breast cancer multicentricity. Monogr Pathol. 1984(25):139–148.
5. Sarnelli R, Squartini F. Multicentricity in breast cancer: a submacroscopic study. Pathol Ann. 1986;21(Pt 1):143–58.
6. Spinelli C, Berti P, Ricci E, Miccoli P. Multicentric breast tumour: an anatomical-clinical study of 100 cases. Eur J Surg Oncol. 1992;18:23–6.
7. Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma OP, Mittra I. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 1996;74:820–4.
8. Wilson LD, Beinfield M, McKhann CF, Haffty BG. Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer. 1993;72:137–42.
9. Leopold KA, Recht A, Schnitt SJ, et al. Results of conservative surgery and radiation therapy for multiple synchronous cancers of one breast. Int J Radiat Oncol Biol Phys. 1989;16:11–6.
10. Kurtz JM, Jacquemier J, Amalric R, et al. Breast-conserving therapy for macroscopically multiple cancers. Ann Surg. 1990;212:38–44.
11. Gentilini O, Botteri E, Rotmensz N, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009;113:577–83.
12. Yerushalmi R, Tyldesley S, Woods R, Kennecke HF, Speers C, Gelmon KA. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Ann Oncol. 2012;23:876–81.
13. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005;11(24 Pt 1):8715–21.
14. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.
15. Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with nonresponsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab – results of the randomised GeparQuinto study (GBG 44). Eur J Cancer. 2013;49:2284–93.
16. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135–44.
17. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28:2024–31.
18. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366:299–309.
19. von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28:2015–23.
20. von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31:3623–30.
21. von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Nat Cancer Inst. 2008;100:542–51.
22. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Nat Cancer Inst. 2008;100:552–62.
23. Oh JL, Dryden MJ, Woodward WA, et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006;24:4971–5.
24. Weissenbacher T, Zschage M, Janni W, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010;122:27–34.
25. Yerushalmi R, Kennecke H, Woods R, Olivotto I, Speers C, Gelmon K. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat. 2009;117:365–70.
26. Kadioglu H, Yucel S, Yildiz S, et al. Feasibility of breast conserving surgery in multifocal breast cancers. Am J Surg. 2014;208:457–64.
27. Lynch SP, Lei X, Chavez-MacGregor M, et al. Multifocality and multicentricity in breast cancer and survival outcomes. Annl Oncol. 2012;23:3063–9.
28. Lynch SP, Lei X, Hsu L, et al. Breast cancer multifocality and multicentricity and locoregional recurrence. Oncologist. 2013;18:1167–73.
29. Moon HG, Han W, Kim JY, et al. Effect of multiple invasive foci on breast cancer outcomes according to the molecular subtypes: a report from the Korean Breast Cancer Society. Ann of Oncol. 2013;24:2298–304.